Payment overview · 2025
General Payments
$243.26
14 reported records · 8 companies
Healthcare provider profile · identity verified
Matthew Robert Porter, MD
Allopathic & Osteopathic Physicians|Family Medicine · WACO, TX · NPI 1023095676
Verified facts
What the public records show
CMS Open Payments records show Matthew Robert Porter, MD received $243.26 in general payments during 2025 across 14 reported records.
PFIZER INC. accounted for 21.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 218 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $51.18 | 21.0% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $44.63 | 18.4% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $43.09 | 17.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.32 | 14.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $27.25 | 11.2% | 1 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $19.49 | 8.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.87 | 6.5% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $6.43 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $243.26 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $44.63 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.32 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $31.95 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $31.95 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $27.25 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $25.87 | 1 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $19.49 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.20 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $6.43 | 1 | 2025 |
Source payment records
|
|||||
| NUVARING Normalized: nuvaring |
Drug | Organon LLC | $6.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 46 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 83 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 125 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
83 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
83 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
125 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
173 | 41 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
218 | 55 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
46 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 495 | 137 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 374 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 310 | 90 |
| Gabapentin | Gabapentin | 258 | 73 |
| Ozempic | Semaglutide | 218 | 55 |
| Trulicity | Dulaglutide | 173 | 41 |
| Lisinopril | Lisinopril | 161 | 46 |
| Levothyroxine Sodium | Levothyroxine Sodium | 153 | 41 |
| Losartan Potassium | Losartan Potassium | 153 | 47 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 139 | 29 |
| Tramadol Hcl | Tramadol Hcl | 134 | 34 |
| Mounjaro | Tirzepatide | 125 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 121 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 119 | 39 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 101 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 100 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 98 | 38 |
| Famotidine | Famotidine | 98 | 35 |
| Trazodone Hcl | Trazodone Hcl | 98 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 96 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 94 | 34 |
| Omeprazole | Omeprazole | 91 | 27 |
| Alprazolam | Alprazolam | 89 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 29 |
| Sertraline Hcl | Sertraline Hcl | 84 | 34 |
| Jardiance | Empagliflozin | 83 | 23 |
| Metformin Hcl Er | Metformin Hcl | 83 | 30 |
| Clonazepam | Clonazepam | 76 | suppressed |
| Furosemide | Furosemide | 76 | 28 |
| Metformin Hcl | Metformin Hcl | 76 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 75 | 24 |
| Prazosin Hcl | Prazosin Hcl | 72 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 68 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 64 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 63 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 62 | 19 |
| Linzess | Linaclotide | 58 | 20 |
| Pregabalin | Pregabalin | 56 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 51 | 17 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 48 | 32 |
| Allopurinol | Allopurinol | 46 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 15 |
| Eliquis | Apixaban | 46 | 16 |
| Buspirone Hcl | Buspirone Hcl | 44 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 39 | 12 |
| Carvedilol | Carvedilol | 38 | 14 |
| Prednisone | Prednisone | 37 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | 14 |
| Simvastatin | Simvastatin | 37 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Ibuprofen | Ibuprofen | 34 | suppressed |
| Lovastatin | Lovastatin | 34 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 34 | suppressed |
| Potassium Chloride | Potassium Chloride | 33 | suppressed |
| Spironolactone | Spironolactone | 33 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 31 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 31 | suppressed |
| Lorazepam | Lorazepam | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 28 | suppressed |
| Rybelsus | Semaglutide | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | 12 |
| Estradiol | Estradiol | 27 | 11 |
| Terconazole | Terconazole | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 26 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 11 |
| Topiramate | Topiramate | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | suppressed |
| Lactulose | Lactulose | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 16 |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 12 |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Phenelzine Sulfate | Phenelzine Sulfate | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Admelog Solostar | Insulin Lispro | 12 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 12 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $243.26 · 14 records | PFIZER INC. | BEXSERO, COMIRNATY, ELIQUIS, JARDIANCE, MOUNJARO, NEXPLANON, NURTEC ODT, NUVARING, PENBRAYA, PREVNAR 20, TRELEGY ELLIPTA, TRUMENBA, The Cologuard Plus Collection Kit, Wegovy, Xelstrym, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error